share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  08/07 07:06
Moomoo AI 已提取核心信息
Clene Inc., a clinical-stage pharmaceutical company, reported financial results for the quarter ended June 30, 2024. The company experienced a net loss of $6.785 million, a significant improvement from the $25.143 million loss in the same period the previous year. Basic and diluted net loss per share was $1.06, compared to $5.84 in the prior year. Revenue from product sales and royalties decreased year-on-year, with product revenue dropping from $226,000 to $64,000 and royalty revenue from $43,000 to $27,000. Operating expenses also saw a reduction, with research and development expenses decreasing by 37% to $4.15 million and general and administrative expenses by 16% to $3.314 million. The company's cash, cash equivalents, and marketable securities stood at $21.7 million as of June 30, 2024. Clene Inc. continues to focus on the development of its lead drug candidate, CNM-Au8, for central nervous system disorders. The company has no drugs approved for commercial sale and relies on revenue from dietary supplements and licensing agreements. Clene Inc. has implemented cost-saving measures and is exploring additional funding options to support its operations.
Clene Inc., a clinical-stage pharmaceutical company, reported financial results for the quarter ended June 30, 2024. The company experienced a net loss of $6.785 million, a significant improvement from the $25.143 million loss in the same period the previous year. Basic and diluted net loss per share was $1.06, compared to $5.84 in the prior year. Revenue from product sales and royalties decreased year-on-year, with product revenue dropping from $226,000 to $64,000 and royalty revenue from $43,000 to $27,000. Operating expenses also saw a reduction, with research and development expenses decreasing by 37% to $4.15 million and general and administrative expenses by 16% to $3.314 million. The company's cash, cash equivalents, and marketable securities stood at $21.7 million as of June 30, 2024. Clene Inc. continues to focus on the development of its lead drug candidate, CNM-Au8, for central nervous system disorders. The company has no drugs approved for commercial sale and relies on revenue from dietary supplements and licensing agreements. Clene Inc. has implemented cost-saving measures and is exploring additional funding options to support its operations.
创尔新药业，一家处于临床阶段的药品公司，公布了截至2024年6月30日的财务报告。公司净亏损678.5万美元，与前一年同期的2514.3万美元相比有了显著改善。基本和摊薄每股净亏损为1.06美元，而去年同期为5.84美元。产品销售和专利权利收入均同比下降，产品销售额从226,000美元降至64,000美元，专利收入从43,000美元降至27,000美元。营业费用也有所减少，研发费用下降37%至415万美元，管理费用下降16%至331.4万美元。该公司截至2024年6月30日的现金、现金等价物和可供出售金融资产合计为2170万美元。创尔新药业继续专注于其治疗中枢神经系统疾病的首席药物候选品CNm-Au8的研发。该公司没有被批准的药品可供商业销售，主要靠膳食补充剂和许可协议收入维持运营。创尔新药业已实施节约成本措施并正在探索其他融资选项以支持运营。
创尔新药业，一家处于临床阶段的药品公司，公布了截至2024年6月30日的财务报告。公司净亏损678.5万美元，与前一年同期的2514.3万美元相比有了显著改善。基本和摊薄每股净亏损为1.06美元，而去年同期为5.84美元。产品销售和专利权利收入均同比下降，产品销售额从226,000美元降至64,000美元，专利收入从43,000美元降至27,000美元。营业费用也有所减少，研发费用下降37%至415万美元，管理费用下降16%至331.4万美元。该公司截至2024年6月30日的现金、现金等价物和可供出售金融资产合计为2170万美元。创尔新药业继续专注于其治疗中枢神经系统疾病的首席药物候选品CNm-Au8的研发。该公司没有被批准的药品可供商业销售，主要靠膳食补充剂和许可协议收入维持运营。创尔新药业已实施节约成本措施并正在探索其他融资选项以支持运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息